



Ángel Guerrero Zotano

Personal Information

Name: GUERRERO ZOTANO Angel Luis, MD,PhD

Date and Place of Birth: January 9, 1976 – Madrid, Spain

Citizenship: Spanish

Current Position: Medical Oncologist. Medical Oncologist, breast cancer specialist, at Instituto Valencian de Oncologia. Profesor Beltrán Báguena, 8.46009. Valencia. Spain.

Contact Information: +34686729280; aguerrero@fivo.org; angel.guerrero.zotano@gmail.com

Education and training:

1994-2000: Degree in Medicine and Surgery in Autonomia University of Madrid, Madrid, Spain.

2001-2005: Residence in Medical Oncology, University Hospital La Fe, Valencia, Spain.

2014-2020: Doctorate cum laude in Medicine from Valencia University, Valencia, Spain.

2005: Three months training at Royal Marsden Hospital's Breast Cancer Unit, London, UK.

2007: Three months training at NYU Langone Medical Center, New York, USA.

2007-2009: Master in Molecular Oncology at CNIO, (Spanish National Cancer Research Center).

2008-2009: Master in Epidemiology and Biostatistic, (Universitat Oberta de Catalunya).

2016: 4-weeks bioinformatics and biostatistics workshop. Vanderbilt CQS. Nashville.USA.

Research and professional experience:

2005-2014: Medical Oncologist, breast cancer specialist, at Instituto Valenciano de Oncologia Valencia, Spain.

2014-2017: Research Fellow, Arteaga Laboratory, Vanderbilt Medical Center, Nashville, USA.

2017-Present: Medical Oncologist, breast cancer specialist, at Instituto Valenciano de Oncologia Valencia, Spain.

2017-Present:Co-chair of translational group (trans-GEICAM) at GEICAM (Spanish Breast Cancer Research Group).

2022-Preset: Co-PI in AURORA project

Technical skills and competences:

Medical skills: Hospital management of cancer patients; management of emergencies; organization of cancer functional units; management of clinical phase I, II, III trials as principal investigator.



CÓRDOBA 2 NOV 2023 | IMIBIC
JORNADAS
CÁNCER DE MAMA Y GESTACIÓN

Clinical trials skills: Design and interpretation of clinical trials in oncology. Medical monitor and participation in steering committee.

Biochemistry: immunoprecipitation/Western blot analysis, ELISA assays.

Cell Biology: cell cultures, cell survival and growth assays, in vitro and in vivo. Flow cytometry.

Molecular Biology: gene silencing via siRNA, RT-PCR, ddPCR, design of mutagenesis project, transfection with viral vectors, DNA and RNA extraction from FFPE tissue. Design and understanding of next generation sequencing projects and Nanostring technology. Bioinformatics skills: Analysis and visual representation of VCF files from DNA and RNA sequencing, R user, cancer datamining.

Awards:

2016: FSEOM-FCRIS: Program for oncology **research** fellowship from Spanish society of medical oncology and CRIS foundation. Grant award: 17000 euros.

2014: PAO-AECC: Program for molecular oncology research fellowship from Spanish society against cancer (AECC). Grant award 48000 euros.

2021: SEOM/FECMA-SAMSUNG grant for research projects in breast cancer: Grant award: 30000 euros.

Main publications in peer reviewed journals (i10-index since 2018: 30)

Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JÁ, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. *Ann Oncol*. 2023 Aug 18:S0923-7534(23)00800-1.

Guerrero-Zotano Á, Belli S, Zielinski C, Gil-Gil M, Fernandez-Serra A, Ruiz-Borrego M, Ciruelos Gil EM, Pascual J, Muñoz-Mateu M, Bermejo B, Margeli Vila M, Antón A, Murillo L, Nissenbaum B, Liu Y, Herranz J, Fernández-García D, Caballero R, López-Guerrero JA, Bianco R, Formisano L, Turner N, Martín M. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer. *Clin Cancer Res*. 2023 Apr 14;29(8):1557-1568.

Asleh K, Lluch A, Goytain A, Barrios C, Wang XQ, Torrecillas L, Gao D, Ruiz-Borrego M, Leung S, Bines J, Guerrero-Zotano Á, García-Sáenz JÁ, Cejalvo JM, Herranz J, Torres R, Haba- Rodriguez J, Ayala F, Gómez H, Rojo F, Nielsen TO, Martín M. Triple-Negative PAM50 Non- Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine. *Clin Cancer Res*. 2023 Jan 17;29(2):389-400



CÓRDOBA 2 NOV 2023 | IMIBIC
JORNADAS
CÁNCER DE MAMA Y GESTACIÓN

Frankie A Holmes , Beverly Moy , Suzette Delalogue , Stephen K L Chia , Bent Ejlersen , Janine Mansi , Hiroji Iwata , Michael Gnant , Marc Buyse , Carlos H Barrios , Tajana Silovski , Robert Šeparović , Anna Bashford , Angel Guerrero Zotano , Neelima Denduluri , Debra Patt , Erhan Gokmen , Ira Gore , John W Smith 2nd, Sibylle Loibl , Norikazu Masuda , Zorica Tomašević Katarina Petráková , Daniel DiPrimeo , Alvin Wong , Miguel Martin , Arlene Chan. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExTeNET): A randomised, double-blind, placebo-controlled, phase 3 trial. *Eur J Cancer* . 2023 May;184:48-59

Axelrod ML, Wang Y, Xu Y, Sun X, Bejan CA, Gonzalez-Ericsson PI, Nunnery S, Bergman RE, Donaldson J, Guerrero-Zotano AL, Massa C, Seliger B, Sanders M, Mayer IA, Balko JM. Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer. *Cancer Res Commun*. 2022 May;2(5):286-292.

Lope V, Guerrero-Zotano A, Ruiz-Moreno E, Bermejo B, Antolín S, Montaña Á, Baena-Cañada JM, Ramos Vázquez M, Fernández de Larrea-Baz N, Chacón JI, García-Sáenz JA, Olier C, Muñoz M, Antón A, Sánchez Rovira P, Arcusa Lanza A, González S, Oltra A, Brunet J, Gavilá Gregori J, Martínez MT, Calvo L, Rosell L, Bezares S, Pastor-Barriuso R, Pérez-Gómez B, Martín M, Pollán M. Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors-Health-EpiGEICAM Study. *Cancers (Basel)*. 2022 Sep 27;14(19):4705

Donat-Vargas C, Guerrero-Zotano Á, Lope V, Bermejo B, Casas A, Baena-Cañada JM, Antolín S, Sánchez-Rovira P, Antón A, Garcia-Saénz JÁ, Ramos M, Muñoz M, de Juan A, Jara Sánchez C, Chacón JI, Gil-Gil M, Andrés Conejero R, Llombart A, Bezares S, Fernández de Larrea-Baz N, Pérez-Gómez B, Martín M, Pollán M. Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study. *Eur J Clin Nutr*. 2022 Sep;76(9):1343-1346. doi: 10.1038/s41430-022-01101-w. Epub 2022

Donat-Vargas C, Guerrero-Zotano A, Casas A, et al. Trajectories of alcohol consumption during life and the risk of developing breast cancer. *Br J Cancer*. 2021;125(8):1168-1176.

Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, Duhem C, Marreaud S, Romagnoli D, Rojas B, Gombos A, Wildiers H, Guerrero-Zotano A, et al. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. *Cancer Discov*. 2021 Nov;11(11):2796-2811.

Servetto A, Kollipara R, Formisano L, Lin CC, Lee KM, Sudhan DR, Gonzalez-Ericsson PI, Chatterjee S, Guerrero-Zotano A, Mendiratta S, Akamatsu H, James N, Bianco R, Hanker AB, Kittler R, Arteaga CL. Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer. *Clin Cancer Res*. 2021 Aug 1;27(15):4379-4396.

Poveda A, Oaknin A, Romero I, Guerrero-Zotano A, Fariñas-Madrid L, Rodriguez-Freixinos V, Mallol P, Lopez-Reig R, Lopez-Guerrero JA. A phase I dose-finding, pharmacokinetics and



CÓRDOBA 2 NOV 2023 | IMIBIC
JORNADAS
CÁNCER DE MAMA Y GESTACIÓN

genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Sci Rep.

2021 Feb 24;11(1):4433.

Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, Muñoz M, Bermejo B, Margeli M, Anton A, Kahan Z, Csösz T, Casas MI, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial- PEARL. Ann Oncol. 2021 Apr;32(4):488-499.

Sudhan, Dhivya R; Guerrero-Zotano, Angel; Won, Helen; Ericsson, Paula González; Servetto, Alberto; Huerta-Rosario, Mariela; Ye, Dan; Lee, Kyung-min; Formisano, Luigi; Guo, Yan; ,Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers, Cancer cell,37,2,183-199. e5,2020.

Lee, Kyung-min; Guerrero-Zotano, Angel L; Servetto, Alberto; Sudhan, Dhivya R; Lin, Chang-Ching; Formisano, Luigi; Jansen, Valerie M; González-Ericsson, Paula; Sanders, Melinda E; Stricker, Thomas P; ,Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer, Nature communications,11,1,1-15,2020.

Lluch, Ana; Barrios, Carlos H; Torrecillas, Laura; Ruiz-Borrego, Manuel; Bines, Jose; Segalla, Jose; Guerrero-Zotano, Ángel; García-Sáenz, Jose A; Torres, Roberto; de la Haba, Juan; ,Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01),Journal of Clinical Oncology,38,3,203-213,2020.

de Larrea-Baz, Nerea Fernández; Pérez-Gómez, Beatriz; Guerrero-Zotano, Ángel; Casas, Ana María; Bermejo, Begoña; Baena-Cañada, José Manuel; Antolin, Silvia; Sánchez-Rovira, Pedro; Vázquez, Manuel Ramos; Garcia-Sáenz, José Ángel; ,Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study,Scientific Reports,10,1,1-13,2020

Lope, Virginia; Guerrero-Zotano, Ángel; Casas, Ana; Bermejo, Begoña; Pérez-Gómez, Beatriz; Criado-Navarro, Inmaculada; Antolín, Silvia; Sánchez-Rovira, Pedro; Ramos-Vázquez, Manuel; Antón, Antonio; ,Serum phospholipids fatty acids and breast cancer risk by pathological subtype,Nutrients,12,10,3132,2020

Martin, Miguel; Guerrero-Zotano, Angel; Montero, Ángel; Jara, Carlos; Filipovich, Elena; Rojo, Federico; Moreno, Fernando; García-Sáenz, Jose Ángel; Alés, Jose Enrique; Chacón, José

Ignacio; ,GEICAM guidelines for the management of patients with breast cancer during the COVID-19 pandemic in Spain,The oncologist.

Guerrero-Zotano A, Stricker T, Hutchinson K E., Formisano L, Schwarz LJ, Estrada V, Giltane J, Kyung-min Lee, Janssen V, Gavilá J, Pérez-Fidalgo A, Lluch A, Ruiz A, Guillem V, Arteaga CL. Genomic profiling of residual ER+ breast cancers treated with prolonged neoadjuvant



CÓRDOBA 2 NOV 2023 | IMIBIC
JORNADAS
CÁNCER DE MAMA Y GESTACIÓN

letrozole reveals novel alterations in clinically resistant tumors. Clin Cancer Res 2018; 24:2517-2529

Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev 2016;35:515-524.

Guerrero-Zotano A, Arteaga CL. Neoadjuvant trials in ER+ breast cancer: A tool for acceleration of drug development and discovery. Cancer Discov 2017; 7(6); 1–14.

Dhivya Sudhan, Luis Schwarz, A. Guerrero-Zotano, Luigi Formisano, Mellissa Nixon, Sarah Croessmann, Paula Gonzalez-Ericsson, Melinda Sanders, Justin Blako, Francesca Avogadri-Connors, Richard Cutler, Alshad Lalani, Richard Bryce, Alan Auerbach, and Carlos Arteaga. Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial. Clin Cancer Res. 2019 Jan 15;25(2):771-783.

Luigi Formisano, Yao Lu, Ariella Hanker, Valerie Jansen, Joshua Bauer, Dhivya Sudhan, Alberto Servetto, Angel Guerrero-Zotano, Yan Guo, Paula Gonzalez Ericsson, Kyung-min Lee, Mellissa Nixon, Luis Schwarz, Melinda Sanders, Teresa Dugger, Marcelo Rocha Cruz, Amir Behdad, Massimo Cristofanilli, Aditya Bardia, Joyce O'Shaughnessy, Rebecca Nagy, Richard Lanman, Nadia Solovieff, Michelle Miller, Fei Su, Yu Shyr, Ingrid Mayer, Justin Balko, and Carlos Arteaga. Aberrant FGFR pathway signaling mediates resistance to CDK4/6 inhibitors therapy in ER+ breast cancer. Nat Commun. 2019 Mar 26;10(1):1373.

Liu ZB, Ezzedine NE, Eterovic AK, Ensor JE, Huang HJ, Albanell J, Choi DS, Lluch A, Liu Y, Rojo F, Wong H, Martínez-Dueñas E, Guerrero-Zotano Á, et al. Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases. Breast Cancer Res Treat. 2019 Nov;178(2):251-261

Lluch A, González-Angulo AM, Casadevall D, Eterovic AK, Martínez de Dueñas E, Zheng X, Guerrero-Zotano Á, et al. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. Eur J Cancer. 2019 Oct;120:54-64

Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, Guerrero-Zotano A, et al. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer. 2019 Aug;117:91-98.



CÓRDOBA 2 NOV 2023 | IMIBIC
JORNADAS
CÁNCER DE MAMA Y GESTACIÓN

Ruíz-Borrego M, Guerrero-Zotano A, Bermejo B, Ramos M, Cruz J, Baena-Cañada JM, Cirauqui B, Rodríguez-Lescure Á, Alba E, Martínez-Jáñez N, Muñoz M, Antolín S, Álvarez I, Del Barco S, Sevillano E, Chacón JI, Antón A, Escudero MJ, Ruiz V, Carrasco E, Martín M; GEICAM. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. *Breast Cancer Res Treat.*

Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano Á, et al. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). *J Clin Oncol.* 2020 Jan 20;38(3):203-213.

Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E. Krop, Howard Burris, John Sweetenham, Angel Guerrero-Zotano, et al. Phase I/Ib dose-escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. *Cancer Chemother Pharmacol.* 2018;82:285-298

Luigi Formisano, Kimberly M. Stauffer, Christian D. Young, Neil E. Bholá, Angel L. Guerrero-Zotano, Valerie M. Jansen, Mónica Valeria Estrada, Katherine E. Hutchinson, Jennifer M. Giltane, Luis J. Schwarz, Yao Lu, Justin M. Balko, Olivier Deas, Stefano Cairo, Jean-Gabriel Judde, Ingrid A. Mayer, Melinda E. Sanders, Teresa C. Dugger, Roberto Bianco, Thomas P. Stricker, Carlos L. Arteaga Association of FGFR1 with estrogen receptor (ER) mediates resistance to endocrine therapy in ER-positive/FGFR1 amplified breast cancer. *Clin Cancer Research* 2017;23:6138-6150.

Kyung-min Lee, Jena M. Giltane, Justin M. Balko, Luis J. Schwarz, Angel Guerrero-Zotano, Katherine E. Hutchinson, Melissa Nixon, Mónica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Henry Gómez, Ana Lluch, Taekyu Lee, Edward T. Olejniczak, Stephen W. Fesik, and Carlos L. Arteaga. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells through regulation of mitochondrial oxidative phosphorylation. *Cell Metabolism* 2017;26(4):633-647.

Luis J. Schwarz, Katherine E. Hutchinson, Brent N. Rexer, Mónica Valeria Estrada, Paula I. Gonzalez-Ericsson, Melinda E. Sanders, Teresa C. Dugger, Luigi Formisano, A. Guerrero-Zotano, Monica Red-Brewer, Christian D. Young, Johan Lantto, Mikkel W. Pedersen, Michael Kragh, Ivan D. Horak, Carlos L. Arteaga. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. *Journal of the National Cancer Institute* 2017;109(11).

M. Martín, J. I. Chacón, A. Antón, A. Plazaola, E. García-Martínez, M.A. Seguí, P. Sánchez-Rovira, J. Palacios, L. Calvo, C. Esteban, E. Espinosa, A. Barnadas, N. Batista, A. Guerrero-Zotano, M. Muñoz; E. Romio; C. Rodríguez-Martín; R. Caballero; M.I. Casas; F. Rojo; E. Carrasco; S. Antolín. Neoadjuvant therapy with weekly nab-Paclitaxel for luminal early breast cancer patients: Results from the Nabrax study (GEICAM/2011-02), a multicenter, non-randomized, phase II trial, with a companion biomarker analysis. *The Oncologist* 2017;22:1301-1308.



CÓRDOBA 2 NOV 2023 | IMIBIC
JORNADAS
CÁNCER DE MAMA Y GESTACIÓN

Ocaña A, Gil-Martin M, Martín M, Rojo F, Antolín S, Guerrero-Zotano A, et al. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. *Oncotarget* 2017;8: 73144–73153..

Cejalvo JM, Martínez de Dueñas E, Galvan P, García-Recio S, Burgués Gasió O, Paré L, Antolin S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano A, Muñoz M, Nuciforo P, Vidal M, Pérez RM, Chacón López-Muñiz JI, Caballero R, Peg V, Carrasco E, Rojo F, Perou CM, Cortes J, Adamo V, Albanell J, Gomis RR, Lluch A, Prat A. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. *Cancer Res* 2017;77:2213-2221.

Herrero-Vicent C, Guerrero-Zotano A, Gavilá-Gregori J, Hernández-Blanquissett A, Sandiego-Contreras S, Samper-Hiraldo JM, Guillem-Porta V, Ruiz-Simón A. A prognostic index for locoregional recurrence after neoadjuvant chemotherapy. *Ecancermedicalscience* 2016; 10:647.

Chan, A., Delaloge, S., Holmes, F.A., Moy, B., Iwata, H., Harvey, V.J., Robert, N.J., Silovski, T., Gokmen, E., von Minckwitz, G., Ejlertsen, B., Chia, S.K.L., Mansi, J., Barrios, C.H., Gnant, M., Buyse, M., Gore, I., Smith, J., Harker, G., Masuda, N., Petrakova, K., Guerrero- Zotano A., Iannotti, N., Rodriguez, G., Tassone, P., Wong, A., Bryce, R., Ye, Y., Yao, B., Martin, M., ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with

HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2016;17: 367–377.

Martín M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, Anton A, Aktas B, Schoenegg W, Muñoz M, Garcia-Saenz JÁ, Gil M, Ramos M, Margeli M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba-Rodriguez JR. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. *J Clin Oncol* 2015; 20:1045-52.

Gavilá J, Guerrero A, Climent MÁ, Fernández A, Gozalbo F, Carrascosa M, Camps J, Guillem V, Ruiz A. Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice. *Int J Clin Oncol* 2015;20:480-9.

Prat, A., Lluch, A., Albanell, J., Barry, W.T., Fan, C., Chacón, J.I., Parker, J.S., Calvo, L., Plazaola, A., Arcusa, A., Seguí-Palmer, M.A., Burgues, O., Ribelles, N., Rodriguez-Lescure, A., Guerrero, A., Ruiz-Borrego, M., Munarriz, B., López, J.A., Adamo, B., Cheang, M.C.U., Li, Y., Hu, Z., Gulley, M.L., Vidal, M.J., Pitcher, B.N., Liu, M.C., Citron, M.L., Ellis, M.J., Mardis, E., Vickery, T., Hudis, C.A., Winer, E.P., Carey, L.A., Caballero, R., Carrasco, E., Martín, M., Perou, C.M., Alba, E.,. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. *Br. J. Cancer* 2014;111:1532-1541.

de Dueñas EM, Hernández AL, Guerrero-Zotano A, Carrión RM, López-Muñiz JI, Novoa SA, Rodríguez AL, Fidalgo JA, Lozano JF, Gasió OB, Carrascal EC, Capilla AH, López-Barajas IB, Mateu MM, de Ceballos Reyna MH, Ferrando AO, Jañez NM, Ballerini VC, Torres AA, Catalán



CÓRDOBA 2 NOV 2023 | IMIBIC
JORNADAS
CÁNCER DE MAMA Y GESTACIÓN

G, Sáenz JA, Menjón S, González-Angulo AM.. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM

2009-03 ConvertHER study. Breast Cancer Res Treat 2014;3:507-15.

Guerrero A, Gavilá J, Folked E, Ortiz B, Martínez F, García A, Climent MA, Guillem V, Ruíz A. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Ann Oncol 2013;24: 674-9.

Guerrero A, Gavilá J, Arribas L and Ruiz A. Primary systemic treatment of HER2-positive metastatic brain disease: profaning the sanctuary. Ann Palliat Med 2012 ;1:202-04.

Guerrero A, Servitja S, Rodríguez-Lescure A, del Barco S, Quintanar MT, Juárez JI, Gayo J, Llobart A, Tusquets I. Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer. Anticancer Drugs 2011;3:283-9.

Llobart-Cussac A, Guerrero A, Galán A, et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Clin Transl Oncol 2012; 2:125-31.

Cardoso F, Bischoff J, Brain E, Guerrero-Zotano A, Lück HJ, Tjan-Heijnen VC, Tanner M, Aapro M. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treat Rev 2013; 39:457-65.

García-Casado Z, Guerrero-Zotano A, Llobart-Cussac A, Calatrava A, Fernández-Serra A, Ruiz-Simon A, Gavilá J, Climent MA, Almenar S, Cervera-Deval J, Campos J, Albaladejo CV, Llobart-Bosch A, Guillem V, López-Guerrero JA. A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer 2010;10:36.

Schneeweiss A, Lauschner I, Ruiz A, Guerrero A, Sánchez-Rovira P, Seguí MA, Goerke K, Wolf M, Manikhas AG, Wacker J, Marmé F, Lichter P, Sinn HP, Sohn C, Mansouri K, Bauknecht T, Hahn M.. Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/

cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase III trial. Clin Breast Cancer 2007;7:555-8.

Guerrero-Zotano A, Muggia F. Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors. Current Cancer Therapy Reviews 2010;11:51-61.

Díaz R, Segura A, Aparicio J, Calderero V, Guerrero A, Pellín L Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature. J Chemother 2004;16:599-603.